ClinicalTrials.gg
Active, not recruitingNCT07514884PeGASUSUpdated Apr 7, 2026

Antimicrobial Stewardship Program Implementation in Brazilian Public Hospitals (PeGASUS)

An interventional study of ASP implementation in Antimicrobial Stewardship Program and Resistance Bacterial, sponsored by Hospital Alemão Oswaldo Cruz. Active, not recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Hospital Alemão Oswaldo Cruz · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Sex
All
01

Study summary

Antimicrobial resistance is a major global public health challenge, leading to increased morbidity, mortality, and healthcare costs. Antimicrobial Stewardship Programs (ASPs) are recognized as an effective strategy to improve the appropriate use of antimicrobials and to reduce the emergence of resistant microorganisms. However, despite national guidelines, many hospitals-especially in low- and middle-income settings-face important barriers to implementing and sustaining these programs.

The PeGASUS study is a nationwide, multicenter implementation initiative designed to support and strengthen ASPs in Brazilian public hospitals. The study will include approximately 54 hospitals across all five regions of Brazil that either do not have an ASP or have programs classified as inadequate or basic.

This is a pragmatic, quasi-experimental before-and-after study with historical control, conducted over approximately 21 months. The intervention combines multiple strategies to address common implementation barriers, including a structured web-based training program, engagement of hospital leadership, development of locally tailored ASP action plans, ongoing technical support, and collaborative learning between participating hospitals.

The study is organized into four phases: (1) pre-intervention (baseline), (2) intervention, (3) follow-up, and (4) wrapping up. During the baseline phase, data on hospital characteristics, antimicrobial use, and ASP organization are collected. During the intervention phase, hospitals receive training and support to implement ASP activities adapted to their local context. The follow-up phase evaluates the sustainability of the implemented strategies under routine conditions.

Outcomes include changes in the level of ASP implementation, antimicrobial consumption (measured as defined daily doses per 1,000 patient-days), number and acceptance of stewardship interventions, and clinical outcomes such as length of hospital stay and 30-day mortality. Additionally, a cost-effectiveness analysis will be conducted in a subset of hospitals.

All data are collected at the hospital level in aggregated form, without identifying individual patients, ensuring confidentiality and minimizing risks.

By combining capacity building, standardized tools, and continuous support, the PeGASUS study aims to bridge the gap between national antimicrobial stewardship guidelines and real-world practice. The findings are expected to provide evidence on scalable strategies to improve antimicrobial use and strengthen healthcare systems, particularly in resource-limited settings.

02

Conditions studied

  • Antimicrobial Stewardship Program
  • Resistance Bacterial
03

In context

Lead sponsor

Hospital Alemão Oswaldo Cruz is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Public hospitals within the Brazilian Unified Health System (SUS)
  • Presence of an established Hospital Infection Prevention and Control (IPC) committee
  • Hospitals without an ASP or with an ASP classified as inadequate or basic, according to a standardized ASP assessment tool
  • Availability of at least one infectious diseases physician (or physician with expertise in infectious diseases) or a clinical pharmacist with expertise in infectious diseases
  • Presence of at least one adult intensive care unit (ICU), including medical, surgical, or coronary ICU
  • Institutional agreement and commitment from hospital leadership to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Hospitals without formal authorization or agreement from institutional leadership to participate in the study
  • Hospitals with adult ICUs currently involved in other antimicrobial stewardship or infection-related intervention studies that could interfere with the outcomes
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Other
    ASP implementation

    ASP implementation

    Other: ASP implementation

Interventions

  • OtherASP implementation

    The PeGASUS intervention is a multifaceted implementation strategy to support the development of Antimicrobial Stewardship Programs (ASPs) in Brazilian public hospitals. Delivered over 10 months, it combines: (1) a structured web-based training program with five modules; (2) development of a locally tailored ASP implementation plan based on national guidelines; (3) engagement of hospital leadership and formation of multidisciplinary ASP teams; (4) ongoing technical support through monthly virtual meetings and at least one on-site visit; (5) collaborative learning and benchmarking sessions across hospitals; and (6) standardized monitoring of antimicrobial use and stewardship activities. This intervention integrates education, mentorship, and locally adapted implementation strategies, aiming to enable hospitals with limited resources to transition from passive antimicrobial monitoring to active stewardship practices.

06

What researchers measure

Primary outcomes

  1. Change in Antimicrobial Stewardship Program (ASP) Implementation Level

    The primary outcome is the change in the organizational level of Antimicrobial Stewardship Programs (ASPs) at the hospital level, measured using a standardized ASP Implementation Level Assessment Questionnaire. This tool classifies hospitals into predefined categories (nonexistent, inadequate, basic, intermediate, or advanced) based on the presence and maturity of core stewardship components. The outcome will be assessed by comparing baseline and post-intervention classifications within each hospital. Changes in ASP level will be analyzed using paired statistical methods, and improvement rates will be reported. This outcome reflects the effectiveness of the intervention in strengthening ASP structure and implementation capacity.

    Time frame: From enrollment to the end of phase 3 at 20 months

Secondary outcomes

  1. Antimicrobial Consumption

    Antimicrobial consumption will be measured at the hospital level using Defined Daily Dose (DDD) per 1,000 patient-days, stratified by antimicrobial classes. Data will be collected monthly and compared between baseline and post-intervention periods.

    Time frame: Baseline (months 0 to 4) and during intervention and follow-up (months 5-20)

  2. Antimicrobial Stewardship Interventions

    This outcome measures the number of interventions performed by the ASP team

    Time frame: Baseline (months 0 to 4) and during intervention and follow-up (months 5-20)

Other outcomes

  1. 30-Day Mortality

    Time frame: Baseline (months 0 to 4) and during intervention and follow-up (months 5-20)

  2. Cost-Effectiveness of ASP Implementation

    A cost-effectiveness analysis will be conducted in a subset of hospitals. The analysis will compare pre- and post-intervention periods, incorporating costs related to antimicrobial use, hospitalization, diagnostics, and human resources

    Time frame: Baseline (months 0 to 4) and during intervention and follow-up (months 5-20)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Sep 20, 2026
CompletionEst.
Oct 1, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514884
Lead sponsor
Hospital Alemão Oswaldo Cruz
Collaborators
ANVISA
Responsible party
Filipe Teixeira Piastrelli (MD, Hospital Alemão Oswaldo Cruz) — Principal investigator
First posted
Apr 7, 2026
Start date
Mar 1, 2025
Primary completion
Sep 20, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Apr 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion